{"name":"AusperBio Therapeutics Inc.","slug":"ausperbio-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AHB-137","genericName":"AHB-137","slug":"ahb-137","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"AHB-137","genericName":"AHB-137","slug":"ahb-137","phase":"phase_3","mechanism":"AHB-137 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTGFjZ2JzeXhWSWhsMGZCR2xTaFVJT0FsQmd6WGJhV2JReWdPNFpKb2N2NHFZRXpMMk1JeFEyb2NwYVNETjNKOUFZMTVoZlpwY3FXNDloRExPVXVuWWd1c0cycHBZd0xwQ2NxWkVHRmdHT1cwYlJTNDE1WHVpNUdtMHBoWWJ5Vi1ESlA5RXRTVHhWcUhnUlZ6dDFJVks1dUc3QnVXNDd6TktpVHo0am5NdWtSMTJDaXdNRTY0Ylo3MXI?oc=5","date":"2025-12-16","type":"pipeline","source":"BioPharma APAC","summary":"AusperBio Reports 30% Functional Cure Rate With AHB 137 In Chronic Hepatitis B - BioPharma APAC","headline":"AusperBio Reports 30% Functional Cure Rate With AHB 137 In Chronic Hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9xSW9rSzQ1M1phVzdFNk9kRUFMV2cwZGNmT2FMOUI4a1pXTTBDZS05Q005VU8wbjlMdU5ZLWNfY0Q5bFhkXzJhQ0pMZ0txWGNVYU1V?oc=5","date":"2025-09-25","type":"pipeline","source":"The Pharma Letter","summary":"AusperBio - The Pharma Letter","headline":"AusperBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQdGJFZGczZHpLSUVGQmYtc1FrUVlMcENudFVWSEZjTmJhZEprSHVTOXRoel8yUDM1a0JZYXByODYwMmN0TEl1MGFzRFVFQ1BWNHktZVFuSmpsUUVHVFRoM01VRWVIWnhpc3l3OWhCS2xlb3JTZnhaa2VOQkxWclpDU2xSLU5rbHdNR1VqWFA3d1pkUzZZNWs3TS1jQTR1SEdpeDc0N2FwVQ?oc=5","date":"2025-09-24","type":"pipeline","source":"The Pharma Letter","summary":"AusperBio raises $73 million to advance hep B candidate - The Pharma Letter","headline":"AusperBio raises $73 million to advance hep B candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQeDUzRUNKVFpfT3dFcjk0VHgtdndhUGNBVThUOEpoUzFLb05SdS1US3hjUDlERHNyU2dvakhlX1laU2FLX1BWMjRvdkU0WTFTcHo2Vzg2bUVOVTluVVZCSmFiSkU5cldkZWo5Z3ppWGxCQWxrekhKSVFuQnh4Z0Zsc3JEYXZ6eUt6ZE56eEF1UkNTemU1YWE4TG9oWm5pOXB5LWxESlM4bjh0TDFQajZzNHhKNFRHU3cwRzF1QTlBaFlYRmx5TC1rS0RHZnh1RlZGS0NtdW05cHJVM19FY01QYURuOTZnWTZQdlp2X2o2aUp3ZHdDM1g4a1U3Uk5sVlE?oc=5","date":"2025-09-21","type":"pipeline","source":"PR Newswire","summary":"AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B - PR Newswire","headline":"AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOTU9ZQ21qSTlaR296UG15Um93NDFLcWs1QVZTMHBOYl9pU2pzdDdXUjJoU2V4djg0R01zNDhMek5UVTdQbzlsXzh2UWR4WTJKM1N3VjZEbktUSHdybGtkOE5VVVlJVTZIVzlYY2M4c0djUG5ocWNBZTdRTjJQS0IwUTBkR1UzUVhRd1RYejNqbW51djF1dUJlZ1Q3RHF1QjJZUU9fYmNrQXZERVlVd0ppRWhSakItUkNoQzJRbEp2YlhOaENOSWdaZjRyX3pTMjlzaGZjYWJYOEo2bTQtb2Nn?oc=5","date":"2025-05-28","type":"pipeline","source":"PR Newswire","summary":"AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B - PR Newswire","headline":"AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQckR2b2tEbnhsVTB5bU9mdjlkaDNiLVRLT3l5a3NBLUJaOWhDaUxWN09nNzRPcUVZeFo1TGI4WG9zSVRuQktXYVlPeHoyZ3ZkbVg3cERmUnlKczRlQmYtdjFVc3ZOWFJncWZhUTMtdS1FYzZGeG9WNHJNTkpINERSSVdiVkRKOUxIdnQzVVV5cnFOTHBxZm8xZ0V0X3A2UkpUc2kwbnM0MTFnMFRPRWxtYk1RTHBZSXppSk9ZZlBWYUt0Xzc2UWkxdnFmYWVHMm1yWkwyOURtZHc5TkRaaTB2dS1GQ2tQUk02alRGSW12dFZqWTVRVHQtUWdR?oc=5","date":"2025-02-11","type":"trial","source":"PR Newswire","summary":"AusperBio Reaches Key Milestone with Dosing Completion and Study Unblinding in Ongoing AHB-137 Phase IIb Trial - PR Newswire","headline":"AusperBio Reaches Key Milestone with Dosing Completion and Study Unblinding in Ongoing AHB-137 Phase IIb Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQMDVqemF2SllMZ2Z3NHhzaVY1OGhUUnBaNXFTUE5UbVhXMnlVZnR5ck1yZHozLUUzNGhHaVpCelU0dmlyc0YyYVFWWEhBdlN4NzNPRzgxVnRaSUtfOTV6NmFiRld1UnhCUEI0cnctRFBJYl9ydnZqQjFSVHd3X1ptTGZoRm9VTi1pSElYaHhrcGdhOGlSdFp1c25WcVpsTzRDeFE?oc=5","date":"2024-12-30","type":"pipeline","source":"BioWorld News","summary":"Ausperbio bags $73M series B for hep B-targeting RNA therapy - BioWorld News","headline":"Ausperbio bags $73M series B for hep B-targeting RNA therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQZUZhMnRaZ3N6MHBVQ3BmcnhMR2d5QmJUdm9waDI0eHlNODVMTDZoYjBJdWUxZUFrNVdxa21MMndYd0lqOHVkdmJaMXNEQXBqVmNTNnM5d1BhZ2lKTklIRk4xbU56Tmp2cDVRQ2ZxVGZadkhSOHN4TV9MVFVtUXhQOGVON3hYX1BmWDBpZXdSNmRKS0VGWlNRMGlwZktrUXhsR1NHR2l0SE81ZUxxSU5xT3gzUU1YbjFyZDlfNlhVOGtqNExNYTlfNmthQWF3TUFhckFVcElBa3YtQzNTM3JtN1RISnMzcTdTQWgxakd3?oc=5","date":"2024-12-26","type":"pipeline","source":"PR Newswire","summary":"AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B - PR Newswire","headline":"AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPcTRhOXlWd1JERnAzT2hQaVZxRkVBSURjWFA5M19QZzgxQURVRk5uM3RBdGtNUnV6VnpDai14eWlLSjlpU2trWjlVVlhURjZNb2NOS3c5ZmgzMTBHQTdvSHAtNkttd2NEYjR0TFB3emVmRWY3bG9DeGRlczR3bUVtaDRlbnhfbUxha0lMRzNIMk9nQTU2NEE5eVlfX0dLcDI0WXl3U3R1WnN3aUk0OEQwMXczdndzNXpXU0JZQ0F4cG96c3dsMnpTNzlwQzdOUlFmMzZpVFBpZ1hBT18wcDFpUlRkNmdPdTg?oc=5","date":"2024-07-10","type":"pipeline","source":"PR Newswire","summary":"AusperBio Receives Breakthrough Therapy Designation for AHB-137 in Chronic Hepatitis B Treatment - PR Newswire","headline":"AusperBio Receives Breakthrough Therapy Designation for AHB-137 in Chronic Hepatitis B Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONjI2THYyOU9rbVhMMDRXU1JWNF9zcjRaT0R2TXR3SU5iQTktN1FYTlY1YzQzSkstRVFGZGxsOWg1RThVWENZTkRmemYyMEhBZzZFWUJZZ2h1YVJzN1NKaVpBSmMzWEU0TXlUbVhaZ0JtLTZDZmxiM1JEU1dBcU1PMg?oc=5","date":"2024-01-04","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}